世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
分子品質管理市場：製品別（独立型、機器別（PCR、DNAシーケンス））、用途別（感染症診断）、分析物タイプ、エンドユーザー別（病院、診断ラボ）-2026年までの世界市場予測Molecular Quality Controls Market by Product (Independent, Instrument Specific (PCR, DNA Sequencing)), Application (Infectious Diseases Diagnostic), Analyte Type, End User (Hospitals, Diagnostic Lab) – Global Forecast to 2026 分子品質管理の市場規模は、2021年の164百万米ドルから2026年には226百万米ドルへと、予測期間中にCAGR6.7％で成長すると予測されています。この市場の成長は主に、第三者品質管理の採用の増加、認定臨床検査室数... もっと見る
日本語のページは自動翻訳を利用し作成しています。 
サマリー分子品質管理の市場規模は、2021年の164百万米ドルから2026年には226百万米ドルへと、予測期間中にCAGR6.7％で成長すると予測されています。この市場の成長は主に、第三者品質管理の採用の増加、認定臨床検査室数の増加、外部品質評価サポートの需要増加、ゲノミクスプロジェクトを支援する政府資金の増加、個別化医薬品の需要増加、シーケンス手順のコスト低下、感染症、癌＆遺伝病の流行増加などの要因によってもたらされています。"予測期間中、独立型コントロールが最大のシェアを占めた" 製品に基づき、分子品質管理市場は、独立型コントロールと機器固有のコントロールに区分されます。2020年の分子品質管理市場では、Independent Controlsセグメントが最大のシェアを占めています。認定ラボの増加や、診断テスト結果の正確性を確保するために規制機関から品質管理の使用を義務付けられていることが、分子品質管理製品市場の成長を後押ししています。 "2020年の分子コントロール市場において、単一分析物コントロール分野が最大のシェアを占めました。" 分子品質管理製品市場は、分析物タイプに基づき、単一分析物タイプと複数分析物タイプに分類されます。シングル分析物コントロールは検査室で非常に好まれ、このセグメントは2020年に分子品質管理製品市場の最大のシェアを占めました。 "2020年、感染症診断部門が分子コントロール市場で最大のシェアを占めた。" 分子品質管理市場は、用途に応じて、感染症診断、腫瘍検査、遺伝子検査、その他の用途に区分されます。2020年の分子品質管理市場では、感染症診断分野が最大のシェアを占めています。このセグメントの大きなシェアは、感染症に対する高度なアッセイの開発、感染症の有病率の大幅な増加、感染症の発生と拡大を抑制するための分子診断技術の有効活用に関する意識の高まりに起因しています。 "2020年の分子品質管理市場において、診断ラボが最大のエンドユーザーセグメント" 本レポートで調査した分子品質管理の主なエンドユーザーは、診断ラボ、病院、IVDメーカーおよびCRO 学術・研究機関、その他のエンドユーザーです。2020年の分子品質管理市場では、診断ラボ部門が最大のシェアを占め、認定診断ラボの増加により、今後数年間で成長機会が見込まれる "アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予測される。" アジア太平洋地域は、予測期間中、分子品質管理市場で最も高い成長率を記録すると予測されています。中国やインドなどの新興国が存在し、この地域の多くの患者層から高品質で正確な診断テストに対する大きな需要があることが、アジア太平洋地域の分子品質管理市場の成長を支える主な要因となっています。 分子品質管理市場で事業を展開するさまざまな主要組織の最高経営責任者（CEO）、マーケティングディレクター、その他のイノベーションおよびテクノロジーディレクター、経営幹部に対して詳細なインタビューを実施しました。 企業タイプ別ティア1：40％、ティア2：30％、ティア3：30 役職別Cレベル経営者：27％、取締役。18％、その他55% 地域別北米：30％、欧州：35％、APAC:北米：30％、欧州：35％、APAC：15％、中南米：10％、中東・アフリカ：5 分子品質管理市場の著名なプレーヤーは、F. Hoffmann-La Roche Ltd.です。(スイス)、Bio-Rad Laboratories, Inc.(米国）、Thermo Fisher Scientific, Inc.(米国)、Randox Laboratories Ltd. (米国)、Thermo Fisher Scientific Inc.(英国）、LGC Limited（英国）、Abbott Laboratories（米国）、Fortress Diagnostics（英国）、SERO AS（ノルウェー）、Anchor Molecular（米国）、Ortho-Clinical Diagnostics, Inc.(米国）、Quidel Corporation（米国）、Sun Diagnostics, LLC（米国）、Seegene Inc.(韓国）、ZeptoMetrix, LLC（米国）、Qnostics（英国）、Bio-Techne Corporation（米国）、Microbiologics, Inc.(米国）、Microbix Biosystems Inc.(カナダ)、SpeeDx Pty.Ltd.(オーストラリア)、Maine Molecular Quality Controls, Inc.(米国)、Grifols, S.A.(スペイン)。 調査対象範囲 本レポートでは、世界の分子品質管理市場を製品、アプリケーション、分析物タイプ、エンドユーザー、地域レベルに基づいて説明、調査しています。また、同市場の成長に影響を与える主要な要因に関する詳細な情報を提供しています。本レポートには、この市場における著名なプレイヤーの詳細な競合分析と製品マトリックス、会社概要、製品ポートフォリオ、最近の開発、MNMの概要が含まれています。 レポート購入の主なメリット 本レポートは、この市場における市場リーダー/新規参入者を支援し、分子品質管理市場全体とそのサブセグメントにおける収益数の最も近い近似値に関する情報を提供します。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけるためのより多くの洞察を得て、適切な市場参入戦略を計画するために役立ちます。また、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供するのに役立ちます。 本レポートでは、以下に関する洞察を提供します。 市場の浸透度。分子品質管理市場におけるトッププレイヤーの製品ポートフォリオに関する包括的な情報。製品、分析物タイプ、アプリケーション、エンドユーザー、地域別にこの市場を分析しています。 市場の発展。製品、分析物の種類、用途、エンドユーザー、地域別に、有利な新興市場に関する包括的な情報を提供します。 市場の多様化。分子品質管理市場における製品ポートフォリオ、成長地域、最近の開発、投資に関する詳細な情報 競合の評価。分子品質管理市場における主要企業の市場シェア、成長戦略、製品提供、能力に関する詳細な評価
SummaryThe molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD 226 million by 2026, at a CAGR of 6.7% during the forecast period. The growth of this market is primarily driven by factors such as the rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines and declining costs of sequencing procedures and increasing prevalence of infectious diseases, cancer & genetic diseases. Table of Contents
1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 YEARS CONSIDERED FOR THE STUDY 32
1.4 CURRENCY 32
TABLE 1 STANDARD CURRENCY CONVERSION RATES 32
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 36
2.1.2 SECONDARY RESEARCH 37
2.1.3 PRIMARY DATA 38
FIGURE 2 PRIMARY SOURCES 38
2.1.3.1 Key data from primary sources 39
FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS 39
2.1.3.2 Breakdown of primary sources 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 40
FIGURE 5 PRIMARY SOURCES 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 BOTTOM-UP APPROACH 42
FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: BOTTOM-UP APPROACH 42
2.2.2 TOP-DOWN APPROACH 43
FIGURE 7 MOLECULAR QUALITY CONTROLS MARKET: TOP-DOWN APPROACH 43
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: MOLECULAR
QUALITY CONTROLS MARKET (2020) 44
FIGURE 10 MARKET SIZE ESTIMATION: PARENT MARKET 45
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
FIGURE 12 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MOLECULAR QUALITY CONTROLS MARKET (2021–2026) 47
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 48
FIGURE 13 DATA TRIANGULATION METHODOLOGY 48
2.4 MARKET SHARE ESTIMATION 49
2.5 ASSUMPTIONS FOR THE STUDY 49
2.6 RISK ASSESSMENT 50
TABLE 2 RISK ASSESSMENT: MOLECULAR QUALITY CONTROLS MARKET 50
2.7 COVID-19 HEALTH ASSESSMENT 50
2.8 COVID-19 ECONOMIC ASSESSMENT 50
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 51
FIGURE 14 CRITERIA IMPACTING THE GLOBAL ECONOMY 51
FIGURE 15 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 52
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR QUALITY CONTROLS MARKET 53
3 EXECUTIVE SUMMARY 54
FIGURE 16 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 54
FIGURE 17 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2021 VS. 2026 (USD MILLION) 55
FIGURE 18 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 55
FIGURE 19 MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 56
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF THE MOLECULAR
QUALITY CONTROLS MARKET 57
4 PREMIUM INSIGHTS 58
4.1 MOLECULAR QUALITY CONTROLS: MARKET OVERVIEW 58
FIGURE 21 INCREASING GOVERNMENT FUNDING TO SUPPORT
GENOMICS PROJECTS TO DRIVE MARKET GROWTH 58
4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 59
FIGURE 22 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2021–2026) 59
4.3 APAC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION
AND COUNTRY (2020) 60
FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MOLECULAR QUALITY CONTROLS
MARKET IN 2020 60
4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHIC MIX 61
FIGURE 24 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 61
4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED VS. DEVELOPING MARKETS 62
FIGURE 25 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING THE FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
FIGURE 26 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.1.1 DRIVERS 64
5.1.1.1 Increasing number of accredited clinical laboratories 64
FIGURE 27 NUMBER OF LABORATORIES THAT RECEIVED CLIA ACCREDITATION,
BY ACCREDITATION ORGANIZATION (2021) 64
5.1.1.2 Growing adoption of third-party quality controls 65
5.1.1.3 Increasing government funding to support genomics projects 65
TABLE 3 GOVERNMENT FUNDING TO SUPPORT GENOMICS 66
5.1.1.4 Increasing demand for personalized medicines and declining
costs of sequencing procedures 66
FIGURE 28 COST OF SEQUENCING PROCEDURES, 2016-2021 67
5.1.1.5 Increasing prevalence of infectious diseases, cancer, &
genetic diseases 67
FIGURE 29 GLOBAL CANCER INCIDENCE, 2020 VS. 2024 68
5.1.1.6 Rising demand for external quality assessment support 68
5.1.2 RESTRAINTS 69
5.1.2.1 Additional costs involved in quality control and budget
constraints in hospitals and laboratories 69
5.1.2.2 Unfavorable reimbursement scenario for molecular tests 69
5.1.3 OPPORTUNITIES 69
5.1.3.1 Rising demand for multi-analyte controls 69
5.1.3.2 Growth opportunities in emerging countries 70
5.1.4 CHALLENGES 70
5.1.4.1 Lack of mandatory regulations for clinical laboratory
accreditation in several emerging countries 70
5.1.4.2 Changing regulatory framework 71
6 INDUSTRY INSIGHTS 72
6.1 INDUSTRY TRENDS 72
6.1.1 INCREASING DEMAND FOR THIRD-PARTY INDEPENDENT QUALITY CONTROLS 72
TABLE 4 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED
BY KEY MARKET PLAYERS 72
6.1.2 CONSOLIDATION OF LABORATORIES 73
6.2 PRICING ANALYSIS 73
TABLE 5 PRICING ANALYSIS OF MOLECULAR QUALITY CONTROL PRODUCTS (2021) 73
FIGURE 30 MOLECULAR QUALITY CONTROL PATENT PUBLICATION TRENDS (JANUARY 2012-JANUARY 2022) 74
FIGURE 31 MOLECULAR QUALITY CONTROLS: TOP 10 COMPANIES WITH THE HIGHEST PATENT APPLICATIONS (2011-2020) 75
FIGURE 32 MOLECULAR QUALITY CONTROLS: TOP 10 PATENT OWNERS (2011-2020) 75
6.3 VALUE CHAIN ANALYSIS 76
FIGURE 33 VALUE CHAIN ANALYSIS 76
6.4 SUPPLY CHAIN ANALYSIS 76
FIGURE 34 SUPPLY CHAIN ANALYSIS 77
6.5 ECOSYSTEM ANALYSIS 77
6.6 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 6 MOLECULAR QUALITY CONTROLS MARKET:
PORTER’S FIVE FORCES ANALYSIS 78
6.6.1 THREAT OF NEW ENTRANTS 78
6.6.2 THREAT OF SUBSTITUTES 78
6.6.3 BARGAINING POWER OF BUYERS 78
6.6.4 BARGAINING POWER OF SUPPLIERS 79
6.6.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 79
6.7 REGULATORY ANALYSIS 79
6.7.1 NORTH AMERICA 79
6.7.1.1 US 79
TABLE 7 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL 80
6.7.1.2 Canada 80
6.7.2 EUROPE 80
TABLE 8 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 81
6.7.3 ASIA PACIFIC 81
6.7.3.1 Japan 81
6.7.3.2 China 82
6.7.3.3 India 82
6.8 TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESS 82
FIGURE 35 MOLECULAR QUALITY CONTROLS MARKET: TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 82
6.8.1 COVID-19 IMPACT ANALYSIS 83
7 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 86
7.1 INTRODUCTION 87
FIGURE 36 INDEPENDENT CONTROLS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET IN 2026 87
TABLE 9 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS 88
TABLE 10 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 89
7.2 INDEPENDENT CONTROLS 89
7.2.1 A WIDE RANGE OF APPLICATIONS AND REDUCTIONS IN OPERATIONAL COSTS HAVE BOOSTED THE ADOPTION OF INDEPENDENT CONTROLS 89
TABLE 11 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED
BY KEY MARKET PLAYERS 90
TABLE 12 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 90
7.3 INSTRUMENT-SPECIFIC CONTROLS 91
TABLE 13 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 91
TABLE 14 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 92
7.3.1 POLYMERASE CHAIN REACTION (PCR) 92
7.3.1.1 Growing use of PCR in proteomics and genomics is a major factor driving market growth 92
TABLE 15 PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.3.2 DNA SEQUENCING & NGS 93
7.3.2.1 Advancements in sequencing technologies to support market growth 93
TABLE 16 DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 94
7.3.3 OTHER TECHNOLOGIES 94
TABLE 17 OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
8 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE 96
8.1 INTRODUCTION 97
FIGURE 37 SINGLE-ANALYTE CONTROLS SEGMENT DOMINATES THE MOLECULAR QUALITY CONTROLS MARKET 97
TABLE 18 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 97
8.2 SINGLE-ANALYTE CONTROLS 98
8.2.1 SIGNIFICANT USE OF SINGLEPLEX ASSAYS IN HOSPITALS IS A KEY FACTOR DRIVING MARKET GROWTH 98
TABLE 19 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 98
8.3 MULTI-ANALYTE CONTROLS 99
8.3.1 INCREASING PREFERENCE FOR MULTI-ANALYTE CONTROLS TO
FUEL MARKET GROWTH 99
TABLE 20 EXAMPLES OF MULTI-ANALYTE CONTROLS 99
TABLE 21 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 100
9 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION 101
9.1 INTRODUCTION 102
FIGURE 38 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET DURING THE FORECAST PERIOD 102
TABLE 22 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 103
9.2 INFECTIOUS DISEASE DIAGNOSTICS 103
9.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 103
TABLE 23 NUMBER OF COVID-19 CASES, BY COUNTRY (2021) 104
TABLE 24 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION) 105
9.3 ONCOLOGY TESTING 105
9.3.1 ONCOLOGY TESTING SEGMENT IS PROJECTED TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 105
TABLE 25 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING,
BY COUNTRY, 2019–2026 (USD MILLION) 106
9.4 GENETIC TESTING 106
9.4.1 ADVANCEMENTS IN GENETIC TESTING TO DRIVE MARKET GROWTH 106
TABLE 26 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2019–2026 (USD MILLION) 107
9.5 OTHER APPLICATIONS 107
TABLE 27 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 108
10 MOLECULAR QUALITY CONTROLS MARKET, BY END USER 109
10.1 INTRODUCTION 110
FIGURE 39 DIAGNOSTIC LABORATORIES SEGMENT TO REGISTER
THE HIGHEST GROWTH IN THE FORECAST PERIOD 110
TABLE 28 MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 110
10.2 DIAGNOSTIC LABORATORIES 111
10.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO PROVIDE GROWTH OPPORTUNITIES IN THE COMING YEARS 111
TABLE 29 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 112
10.3 HOSPITALS 112
10.3.1 GROWING PATIENT VOLUME IS DRIVING THE ADOPTION OF MOLECULAR QUALITY CONTROLS AMONG HOSPITALS 112
TABLE 30 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION) 113
10.4 IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS 114
10.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES
TO SUPPORT MARKET GROWTH 114
TABLE 31 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2019–2026 (USD MILLION) 114
10.5 ACADEMIC & RESEARCH INSTITUTES 115
10.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS
TO DRIVE MARKET GROWTH 115
TABLE 32 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 115
10.6 OTHER END USERS 116
TABLE 33 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION) 116
11 MOLECULAR QUALITY CONTROLS MARKET, BY REGION 117
11.1 INTRODUCTION 118
TABLE 34 MOLECULAR QUALITY CONTROLS MARKET, BY REGION,
2019–2026 (USD MILLION) 118
11.2 NORTH AMERICA 118
FIGURE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 119
TABLE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 36 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 120
TABLE 37 NORTH AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 120
TABLE 38 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 121
TABLE 39 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 121
TABLE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 121
11.2.1 US 122
11.2.1.1 Increasing CLIA accreditation for clinical laboratories is driving the market for molecular quality controls in the US 122
FIGURE 41 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION,
BY ORGANIZATION (2018) 122
TABLE 41 US: KEY MACROINDICATORS 123
TABLE 42 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 123
TABLE 43 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 123
TABLE 44 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 124
TABLE 45 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 124
TABLE 46 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
11.2.2 CANADA 125
11.2.2.1 Canada has a well-established and well-funded
biomedical research sector 125
TABLE 47 CANADA: KEY MACROINDICATORS 125
TABLE 48 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 126
TABLE 49 CANADA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 126
TABLE 50 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 126
TABLE 51 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 127
TABLE 52 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 127
11.3 EUROPE 127
FIGURE 42 EUROPE: CANCER PREVALENCE, BY COUNTRY 128
TABLE 53 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
TABLE 54 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 55 EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 129
TABLE 56 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 130
TABLE 57 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 130
TABLE 58 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
11.3.1 GERMANY 131
11.3.1.1 Increasing number of certified laboratories and the rising volume of high-quality tests performed by these laboratories to support market growth in Germany 131
TABLE 59 GERMANY: KEY MACROINDICATORS 131
TABLE 60 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 132
TABLE 61 GERMANY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 132
TABLE 62 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 132
TABLE 63 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 133
TABLE 64 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 133
11.3.2 FRANCE 134
11.3.2.1 Increasing prevalence of infectious diseases and growing demand for early diagnosis to drive market growth 134
TABLE 65 FRANCE: KEY MACROINDICATORS 134
TABLE 66 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 134
TABLE 67 FRANCE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 135
TABLE 68 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 135
TABLE 69 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
TABLE 70 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 136
11.3.3 UK 136
11.3.3.1 Growth in the life science industry and increased research to drive market growth in the UK 136
TABLE 71 UK: KEY MACROINDICATORS 137
TABLE 72 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 137
TABLE 73 UK: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 138
TABLE 74 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 138
TABLE 75 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 138
TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
11.3.4 ITALY 139
11.3.4.1 Growing disease prevalence to drive the demand for better and more accurate disease diagnosis in Italy 139
TABLE 77 ITALY: KEY MACROINDICATORS 140
TABLE 78 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 140
TABLE 79 ITALY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 140
TABLE 80 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 141
TABLE 81 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 141
TABLE 82 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 141
11.3.5 SPAIN 142
11.3.5.1 Increasing demand for prenatal and genetic testing and rising focus on laboratory consolidation to support market growth in Spain 142
TABLE 83 SPAIN: KEY MACROINDICATORS 143
TABLE 84 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 143
TABLE 85 SPAIN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 143
TABLE 86 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 144
TABLE 87 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 88 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 144
11.3.6 RUSSIA 145
11.3.6.1 Increasing acceptance of molecular diagnostics-based personalized medicine to drive market growth 145
TABLE 89 RUSSIA: DISEASE STATISTICS (2020) 145
TABLE 90 RUSSIA: POPULATION AND CANCER STATISTICS 145
TABLE 91 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 145
TABLE 92 RUSSIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 146
TABLE 93 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 146
TABLE 94 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 146
TABLE 95 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 147
11.3.7 REST OF EUROPE 147
TABLE 96 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 147
TABLE 97 REST OF EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 148
TABLE 98 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 148
TABLE 99 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 148
TABLE 100 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 149
11.4 ASIA PACIFIC 149
FIGURE 43 ASIA PACIFIC: CANCER PREVALENCE 150
FIGURE 44 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 151
TABLE 101 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 152
TABLE 102 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 152
TABLE 103 ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 152
TABLE 104 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 153
TABLE 105 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 153
TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 153
11.4.1 JAPAN 154
11.4.1.1 Well-developed healthcare system and the rising demand for improvements in the quality of IVD test results to drive market growth in Japan 154
TABLE 107 JAPAN: KEY MACROINDICATORS 154
TABLE 108 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 154
TABLE 109 JAPAN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 155
TABLE 110 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 155
TABLE 111 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 156
11.4.2 CHINA 156
11.4.2.1 Growing access to modern healthcare and government support to boost the market growth in China 156
TABLE 113 CHINA: KEY MACROINDICATORS 157
TABLE 114 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 157
TABLE 115 CHINA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 157
TABLE 116 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 158
TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 118 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 158
11.4.3 INDIA 159
11.4.3.1 Rising need to secure NABL accreditations to drive the demand for quality controls in India 159
FIGURE 45 INDIA: INCREASING NUMBER OF LABS WITH NABL ACCREDITATIONS,
2012–2020 159
TABLE 119 INDIA: KEY MACROINDICATORS 160
TABLE 120 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 160
TABLE 121 INDIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 160
TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 161
TABLE 123 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 161
TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 161
11.4.4 REST OF ASIA PACIFIC 162
TABLE 125 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 163
TABLE 126 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 163
TABLE 127 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY ANALYTE TYPE, 2019–2026 (USD MILLION) 163
TABLE 128 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 164
TABLE 129 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 164
11.5 LATIN AMERICA 165
11.5.1 RISING INCIDENCE OF SEVERAL INFECTIOUS DISEASES TO
DRIVE MARKET GROWTH 165
TABLE 130 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 166
TABLE 131 LATIN AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 166
TABLE 132 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 166
TABLE 133 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 167
TABLE 134 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 167
11.6 MIDDLE EAST & AFRICA 168
11.6.1 GROWING GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH 168
TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 168
TABLE 136 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 169
TABLE 137 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY ANALYTE TYPE, 2019–2026 (USD MILLION) 169
TABLE 138 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 169
TABLE 139 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 170
12 COMPETITIVE LANDSCAPE 171
12.1 MARKET OVERVIEW 171
12.2 KEY PLAYER STRATEGIES 172
12.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 173
12.4 MARKET RANKING ANALYSIS 174
FIGURE 47 RANK OF COMPANIES IN THE GLOBAL MOLECULAR QUALITY CONTROLS MARKET (2020) 174
12.5 COMPETITIVE LEADERSHIP MAPPING 175
12.5.1 STARS 176
12.5.2 EMERGING LEADERS 176
12.5.3 PERVASIVE PLAYERS 176
12.5.4 PARTICIPANTS 176
FIGURE 48 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 178
12.6.1 PROGRESSIVE COMPANIES 178
12.6.2 STARTING BLOCKS 178
12.6.3 RESPONSIVE COMPANIES 178
12.6.4 DYNAMIC COMPANIES 178
FIGURE 49 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 179
12.7 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS 180
FIGURE 50 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR QUALITY CONTROLS MARKET 180
12.8 COMPANY GEOGRAPHIC FOOTPRINT 181
12.8.1 GEOGRAPHIC REVENUE MIX: KEY PLAYERS 181
TABLE 140 COMPANY END-USER FOOTPRINT (20 COMPANIES) 182
TABLE 141 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 183
12.9 COMPETITIVE SITUATION AND TRENDS 184
12.9.1 MOLECULAR QUALITY CONTROLS MARKET: PRODUCT LAUNCHES & REGULATORY APPROVALS 184
TABLE 142 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 184
12.9.2 MOLECULAR QUALITY CONTROLS MARKET: KEY DEALS 186
TABLE 143 KEY DEALS 186
13 COMPANY PROFILES 190
13.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 LGC LIMITED 190
TABLE 144 LGC LIMITED: BUSINESS OVERVIEW 190
FIGURE 51 LCG LIMITED: COMPANY SNAPSHOT (2021) 191
13.1.2 THERMO FISHER SCIENTIFIC 197
TABLE 145 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 197
FIGURE 52 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 198
13.1.3 BIO-RAD LABORATORIES, INC. 204
TABLE 146 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 204
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 205
13.1.4 MICROBIOLOGICS, INC. 209
TABLE 147 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 209
13.1.5 ABBOTT LABORATORIES 215
TABLE 148 ABBOTT LABORATORIES: BUSINESS OVERVIEW 215
FIGURE 54 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 216
13.2 OTHER PLAYERS 219
13.2.1 ROCHE DIAGNOSTICS 219
TABLE 149 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 219
FIGURE 55 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020) 220
13.2.2 ZEPTOMETRIX, LLC 223
TABLE 150 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW 223
13.2.3 QUIDEL CORPORATION 229
TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW 229
FIGURE 56 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 230
13.2.4 QNOSTICS 232
TABLE 152 QNOSTICS: BUSINESS OVERVIEW 232
13.2.5 MAINE MOLECULAR QUALITY CONTROLS, INC. 236
TABLE 153 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW 236
13.2.6 RANDOX LABORATORIES LTD. 239
TABLE 154 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 239
13.2.7 BIO-TECHNE CORPORATION 242
TABLE 155 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 242
FIGURE 57 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 243
13.2.8 FORTRESS DIAGNOSTICS 245
TABLE 156 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW 245
13.2.9 MICROBIX BIOSYSTEMS 247
TABLE 157 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW 247
FIGURE 58 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2021) 248
13.2.10 GRIFOLS, S.A. 252
TABLE 158 GRIFOLS, S.A.: BUSINESS OVERVIEW 252
FIGURE 59 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020) 253
13.2.11 ORTHO CLINICAL DIAGNOSTICS 255
TABLE 159 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW 255
FIGURE 60 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020) 256
13.2.12 ANCHOR MOLECULAR 258
TABLE 160 ANCHOR MOLECULAR: BUSINESS OVERVIEW 258
13.2.13 SPEEDX PTY. LTD. 259
TABLE 161 SPEEDX PTY. LTD.: BUSINESS OVERVIEW 259
13.2.14 SERO AS 262
TABLE 162 SERO AS: BUSINESS OVERVIEW 262
13.2.15 SEEGENE INC. 263
TABLE 163 SEEGENE INC.: BUSINESS OVERVIEW 263
FIGURE 61 SEEGENE INC: COMPANY SNAPSHOT (2020) 264
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 268
14.1 DISCUSSION GUIDE 268
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 272
14.3 AVAILABLE CUSTOMIZATIONS 274
14.4 RELATED REPORTS 274
14.5 AUTHOR DETAILS 275
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（バイオ薬物）の最新刊レポート
MarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD（dna sequencing）の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/07/05 10:26 162.17 円 175.82 円 209.73 円 |
